Axsome Therapeutics is a biopharmaceutical company developing therapies for the management of central nervous system (CNS) conditions that have limited treatment options. Co.'s primary CNS portfolio includes: AXS-05, which is an oral, investigational N-methyl-D-aspartate receptor antagonist with multimodal activity under development for the treatment of CNS disorders; AXS-07, which is an oral, multi-mechanistic, investigational medicine under development for the acute treatment of migraine; AXS-12, which is an oral, investigational medicine in development for the treatment of narcolepsy; and AXS-14, which is an oral, investigational medicine in development for the treatment of fibromyalgia. We show 35 historical shares outstanding datapoints in our coverage of AXSM's shares outstanding history.
Understanding the changing numbers of AXSM shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AXSM versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AXSM by allowing them to research AXSM shares outstanding history
as well as any other stock in our coverage universe. |
Free AXSM Email Alerts:
Video: Shares Outstanding Importance
